Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

Opinion
Video

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Samer A. Srour, MB ChB, MS
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Related Content
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article
Carrie L. Kitko, MD, associate professor, pediatrics, medical director, the Pediatric Stem Cell Transplantation Program, the Ingram Professor of Pediatric Oncology, Monroe Carell Jr. Children’s Hospital at Vanderbilt; Sagar S. Patel, MD, director, Communications and Media Relationships, the Division of Hematology, the University of Utah Huntsman Cancer Institute

Kitko and Patel Emphasize the Importance of GVHD Research and Awareness

February 19th 2024
Podcast
Press Release

Fox Chase Cancer Center and Temple University Hospital Recertified Under ASCO’s Quality Oncology Practice Initiative

April 12th 2024
Article
Yara Abdou, MD

Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer

December 7th 2023
Podcast
Andres F. Correa, MD

European Urology Names Fox Chase Cancer Center’s Dr. Andres F. Correa Reviewer of the Month

April 10th 2024
Article
Professor Jun Guo, MD, PhD, from Peking University Cancer Hospital

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

April 9th 2024
Article